The popularity of Sildenafil initially fueled a boom for pharma, however recent developments present a murky outlook for investors. Lower-cost competitors are eroding revenue, and continued litigation add additional https://phoebecnyi723987.blognody.com/50207386/viagra-and-big-pharma-a-volatile-play